A Report on the Results of the COMFORT-I and COMFORT-II Trials of the JAK1/JAK2 Inhibitor Ruxolitinib for Myelofibrosis


A Report on the Results of the COMFORT-I and COMFORT-II Trials of the JAK1/JAK2 Inhibitor Ruxolitinib for Myelofibrosis
Slides from presentations at ASCO 2011

Harrison CN et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). Proc ASCO 2011;Abstract LBA6501.